Nevirapina Kern Pharma (Nevirapine)

Nevirapine, the active ingredient in Nevirapina Kern Pharma, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as a strength/form for oral use. It treats HIV-1 infection in adults and children by inhibiting viral replication. GNH USA supplies Nevirapina Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapina (nevirapine) is an antiretroviral that targets the HIV‑1 reverse transcriptase enzyme. - HIV‑1 infection (treatment‑naïve adults): reduces viral load and helps restore immune function. - HIV‑1 infection (treatment‑experienced adults): provides an alternative regimen when resistance to other agents is present. - HIV‑1 infection in pediatric patients: used as part of combination therapy to control viral replication.

Nevirapine may cause a range of adverse reactions.

Common Side Effects: - Rash: mild to moderate skin eruption. - Nausea: occasional gastrointestinal upset. - Fatigue: feeling of tiredness or weakness. - Headache: mild to moderate intensity. - Abdominal pain: discomfort in the stomach area. - Dizziness: transient sense of light‑headedness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate discontinuation. - Hepatic failure: signs of liver injury such as jaundice or elevated enzymes. - Severe hypersensitivity reactions: including fever, eosinophilia, or organ involvement. - Neutropenia: marked reduction in white blood cells. - Severe anemia: significant drop in red blood cell count. - Life‑threatening rash with mucosal involvement.

Nevirapina requires careful monitoring to minimize risks. - Liver function monitoring: assess baseline transaminases and repeat periodically during therapy. - Skin reactions: discontinue immediately if severe rash, Stevens‑Johnson syndrome, or toxic epidermal necrolysis develop. - Hematologic monitoring: perform regular CBC to detect neutropenia or anemia. - Drug interactions: avoid concomitant use with potent CYP3A inducers such as rifampicin or St. John's wort. - Pregnancy and breastfeeding: evaluate risk‑benefit; use only if clearly needed. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Nevirapina can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Rifampicin (rifampin): induces metabolism, markedly lowers nevirapine concentrations, risking treatment failure. - St. John's wort: potent CYP3A4 inducer that may reduce therapeutic effect. - Carbamazepine: enzyme inducer that decreases nevirapine exposure.

Moderate Interactions (Monitor Closely): - Protease inhibitors (ritonavir, lopinavir): can increase nevirapine levels, raising risk of toxicity. - Fluconazole: CYP3A4 inhibitor that may raise nevirapine concentrations. - Hormonal contraceptives: nevirapine may reduce contraceptive efficacy; consider alternative or additional methods.